Eli Lilly eyes Kelonia Therapeutics in $7B deal with $3.25B to be paid up front, and before investors could buy. How to get in early on market moves
Biotech is big business.
Hosted on MSN
Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
Eli Lilly said on Monday it will acquire privately held Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker deepens its presence in next-generation cancer treatments. The agreement ...
JD Supra
Eli Lilly to Acquire Kelonia Therapeutics
On April 20, 2026, Eli Lilly & Company (“Lilly”) and Kelonia Therapeutics, Inc. (“Kelonia”) announced an agreement for Lilly to acquire Kelonia in an all-cash transaction expected to close in the ...
Reuters
Eli Lilly to buy Boston's Kelonia for up to $7 billion in cancer push
Kelonia specializes in 'in vivo' CAR-T therapies for cancer Deal includes $3.25 bln upfront and milestone payments Deal price reflects strong data and sector competition - analyst April 20 (Reuters) - ...
FierceBiotech
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example of the sky-high prices that Big Pharmas are willing to pay for in vivo CAR-T tech. In fact, it was the ...
FierceBiotech
ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
Kelonia Therapeutics has shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech. All 18 ...